Parsippany, January 23, 2013 – Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has completed the acquisition of Belgium-based Uteron Pharma SA for $150 million in cash up front, and up to $155 million in potential future milestone (...)
Following the successful completion of a 14 million EUR capital raise in April 2012, Uteron Pharma continues to evaluate its options for future funding of its product portfolio. A public offering is being considered.
Liege, March 28 2012 – Uteron Pharma successfully completed a 14 million EUR capital increase. This new equity round enables Uteron Pharma to further finance its strong growth ambitions as a specialist in female healthcare.
Uteron, represented by François Fornieri (CEO), participated to the economic mission led by HRH Prince Philippe in Chile from 3th to 7th December 2011. This mission has focused primarily on the capital, Santiago.
Uteron, represented by François Fornieri (CEO), participated to the mission led by HRH Prince Philippe in the Republic of China from 20 to 29 October 2011 as part of the cooperation agreement between federal authority and Regions. Several areas were targeted during this mission such as Life (...)
With an additional investment of €1,5 million, the Walloon investment company SRIW confirms its confidence in the growth potential of Uteron Pharma, a dedicated female healthcare company located in Liège.